Inventor · disambiguated record
Bahram Valamehr
Also filed as: VALAMEHR BAHRAM
34 granted patents·36 pending applications·189 citations·filing 2005–2025
97Inventor score
Top patents by PatentIndex Score
70 records- 0198US10947505B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2020·Granted Mar 16, 2021·8 cites·20 claims
- 0297US11365394B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2021·Granted Jun 21, 2022·14 cites·20 claims
- 0397US11162076B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2021·Granted Nov 2, 2021·7 cites·29 claims
- 0497US11162075B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2020·Granted Nov 2, 2021·5 cites·10 claims
- 0597US10626372B1Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2016·Granted Apr 21, 2020·21 cites·16 claims
- 0696US10927346B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2019·Granted Feb 23, 2021·17 cites·22 claims
- 0796US10858628B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2016·Granted Dec 8, 2020·15 cites·25 claims
- 0896US10287606B2Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2017·Granted May 14, 2019·28 cites·24 claims
- 0996US10023879B2Minimal volume reprogramming of mononuclear cellsFATE THERAPEUTICS INC·Filed 2015·Granted Jul 17, 2018·13 cites·23 claims
- 1095US11072781B2Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2019·Granted Jul 27, 2021·18 cites·18 claims
- 1195US10954529B2Minimal volume reprogramming of mononuclear cellsFATE THERAPEUTICS INC·Filed 2018·Granted Mar 23, 2021·8 cites·15 claims
- 1294US10844356B2Cell culture platform for single cell sorting and enhanced reprogramming of iPSCsFATE THERAPEUTICS INC·Filed 2017·Granted Nov 24, 2020·7 cites·20 claims
- 1391US11634688B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2020·Granted Apr 25, 2023·2 cites·11 claims
- 1489US11413309B2Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2017·Granted Aug 16, 2022·4 cites·26 claims
- 1589US11096964B2Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2017·Granted Aug 24, 2021·4 cites·31 claims
- 1688US9732319B2Cell culture platform for single cell sorting and enhanced reprogramming of iPSCsVALAMEHR BAHRAM·Filed 2011·Granted Aug 15, 2017·10 cites·13 claims
- 1787US11352607B2Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2019·Granted Jun 7, 2022·2 cites·28 claims
- 1887US11268069B2Reprogramming methods and cell culture platformsFATE THERAPEUTICS INC·Filed 2015·Granted Mar 8, 2022·4 cites·13 claims
- 1985US12385012B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2023·Granted Aug 12, 2025·0 cites·15 claims
- 2082US11441126B2Platform for the induction and maintenance of ground state pluripotencyFATE THERAPEUTICS INC·Filed 2016·Granted Sep 13, 2022·2 cites·21 claims
- 2178US12410403B2Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2021·Granted Sep 9, 2025·0 cites·20 claims
- 2276US2025032547A1Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumorsFATE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2375US12203098B2Cells having solid tumor targeting backbone and use thereofFATE THERAPEUTICS INC·Filed 2023·Granted Jan 21, 2025·0 cites·30 claims
- 2475US12173274B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2021·Granted Dec 24, 2024·0 cites·22 claims
- 2574US12264322B2Minimal volume reprogramming of mononuclear cellsFATE THERAPEUTICS INC·Filed 2021·Granted Apr 1, 2025·0 cites·23 claims
- 2673US12419870B2Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2022·Granted Sep 23, 2025·0 cites·16 claims
- 2773US12415989B2Cell culture platform for single cell sorting and enhanced reprogramming of iPSCsFATE THERAPEUTICS INC·Filed 2020·Granted Sep 16, 2025·0 cites·11 claims
- 2873US12398373B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2018·Granted Aug 26, 2025·0 cites·26 claims
- 2973US12122846B2Chimeric antigen receptor for tumor targetingFATE THERAPEUTICS INC·Filed 2023·Granted Oct 22, 2024·0 cites·16 claims
- 3073US2025145966A1Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3172US12351831B2Platform for the induction and maintenance of ground state pluripotencyFATE THERAPEUTICS INC·Filed 2022·Granted Jul 8, 2025·0 cites·20 claims
- 3272US12281329B2Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2021·Granted Apr 22, 2025·0 cites·27 claims
- 3372US2021324340A1Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3472US2025228943A1Cells having solid tumor targeting backbone and use thereofFATE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3570US2025215396A1Compositions and methods for immune cell modulation in adoptive immunotherapiesFATE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3670US2025222029A1Chimeric antigen receptor for tumor targetingFATE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3769US12275955B2Combining iPSC derived effector cell types for immunotherapy useFATE THERAPEUTICS INC·Filed 2021·Granted Apr 15, 2025·0 cites·40 claims
- 3869US2025000904A1Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumorsFATE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3967US2022228125A1Reprogramming methods and cell culture platformsFATE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4067US2018072992A1Methods and compositions for inducing hematopoietic cell differentiationFATE THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4167US2020172870A1Cells with increased immuno-regulatory properties and methods for their use and manufactureFATE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4266US2025339532A1Stealth strategy engaging immune recognition pathways for use in allogeneic cell therapiesFATE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4364US2024158747A1Composition and methods for inducing myeloid suppressive cells and use thereofFATE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4463US2025388646A1Enhancing effector cell durability and efficacy in adoptive cell therapiesFATE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4563US2025313802A1Combining ipsc derived effector cell types for immunotherapy useFATE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4662US2025263670A1Cellular reprogramming using temporal and transient plasmid vector expression systemFATE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4761US2021163622A1Immune effector cell engineering and use thereofFATE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4860US12435123B2Immunotherapies using enhanced iPSC derived effector cellsFATE THERAPEUTICS INC·Filed 2019·Granted Oct 7, 2025·0 cites·28 claims
- 4960US2025018034A1Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumorsFATE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 5059US12247226B2Cellular reprogramming using temporal and transient plasmid vector expression systemFATE THERAPEUTICS INC·Filed 2018·Granted Mar 11, 2025·0 cites·39 claims
Showing the top 50 of 70 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Bahram Valamehr files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →